Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response.
Active tuberculosis (TB) infection including asymptomatic and extrapulmonary disease may be detected with 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). This report highlights the promising role of FDG-PET/CT for evaluation of TB in high-risk, immunocompromised patients with cancer. PET/CT performed for cancer evaluation may detect asymptomatic infection and guide definitive diagnosis. It may also be a useful tool in the assessment of latent TB, to exclude active disease prior to treatment. PET/CT has potential for monitoring response to anti-tuberculosis treatment. Metabolic response may indicate clinical response and guide duration of anti-microbial therapy.
Hofmeyr
Ann
A
Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia. Ann.hofmeyr@sswahs.nsw.gov.au
Lau
W F Eddie
WF
Slavin
Monica A
MA
D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003937:Diagnosis, Differential; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D016867:Immunocompromised Host; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008477:Mediastinal Diseases / Q000000981:diagnostic imaging*; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D049268:Positron-Emission Tomography / Q000379:methods; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D014388:Tuberculosis, Lymph Node / Q000000981:diagnostic imaging*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18